The method of treatment of cerebral palsy

 

(57) Abstract:

The invention relates to medicine, namely, neurology, and can be used in the treatment of cerebral palsy. The method involves the injection of such drugs as oxitetraciclina succinate. Moreover, the infant intramuscularly 25 mg oxitetraciclina succinate 1 time per day for 12 days with a repeat treatment after 6 months and increasing doses of the specified drug to 50 mg; and the child is older than 1 year intramuscularly 50 mg oxitetraciclina succinate 1 time per day for 16 days with a repeat course of treatment within 1 year to improve cognitive functions. The method allows to reduce the treatment time due to more rapid recovery and improved brain function than previously known methods. 1 PL.

The present invention relates to medicine, namely to neurology and can be used in the treatment of cerebral palsy various etiologies.

The essence of the method is that the patient up to 1 year injected 25-50 mg oxitetraciclina succinate in 10 ml of saline solution 1 once a day for 12 days with repeat treatment after 6 mesaria 16 days with a repeat course of treatment within 1 year to improve cognitive functions.

For protection of the invention given the chemical name “oxitetraciclina succinate”. This removed the issue of synonyms: Mexidol, Oxidant, Mexicor, known as a trademark. (table).

The known method [1] treatment of cerebral palsy, selected as a prototype. He also has disadvantages: slow and mild recovery of lost functions, long treatment time, repetition of courses.

In the proposed invention the task is solved faster restore and improve function of damaged brain and the reduction of treatment time; reduced cost of treatment.

This problem is solved by the fact that the infant is injected intramuscularly 25 mg oxitetraciclina succinate 1 time per day for 12 days with a repeat treatment after 6 months and increasing doses of the specified drug to 50 mg; and the child is older than 1 year intramuscularly 50 mg oxitetraciclina succinate 1 time per day for 16 days with a repeat course of treatment within 1 year to improve cognitive functions.

Detailed description of the method

The method is based on the basis of biochemical steps 2-ethyl-6-METI the BA in curative substance causes the following mechanism of endogenous effects, confirmed authors experimentally: inhibits lipid peroxidation, increases the ratio of lipid-protein, reduces the viscosity of the membrane and increases its fluidity; increases the content in the brain of dopamine.

The method is performed in the following sequence.

The patient up to 1 year appointed intravenous bolus of 25 mg oxitetraciclina succinate in 10 ml of saline 1 time per day. If you enter less than 25 mg of the drug, some cases do not reach the antihypoxic effect. If you enter more than 25 mg, the effect is dramatically increased. The treatment for 12 days. After the 5th session see the reduction cyanosis of the skin, improving the physical activity of the child; becomes more loud cry. By the end of the first course of treatment achieve the stabilization of the neurological status of the child.

After 6 months of repeat treatment with simultaneous implementation of a proportional increase in dose up to 50 mg in saline solution. This increase is dose adequately for future growth and development of the child. See the following step increase physical activity. Face more meaningful, the child begins to distinguish color, reacts to sound, learns radiotelevisione 50 mg oxitetraciclina succinate 1 time per day for 16 days. After 7 session see significant improvement in motor and intellectual functions. The child becomes calmer. Normal sleep.

After 16 session, after the first treatment, the patient received fixed positive effect leveling motor disorders. Improved: learning, memory, attention and other cognitive functions. Baby is sleeping more quietly.

Within 1 year, repeat the treatment suggested for children over 1 year method. Reach further improve nestico-intellectual functions of the brain. Reduce the backlog of physical and mental spheres from their peers. The child becomes more accommodating in the children's team. Psychologically get free.

Clinical examples

Example 1. A newborn boy. State record No. 6. The first minutes after the end of term labor. Born in the blue asphyxia, with a tight umbilical cord entanglement around his neck. The skin bluish color. The child is listless, dinamiche. Not screaming.

Newborn injected 25 mg oxitetraciclina succinate in 10 ml of saline. See 2 hours: pale skin color, the initial movement of the limbs, krina 7 day a child begins to suck the mother's breast, but does swallowing inadequate. The skin is a normal color. Restored CSR. Actively moves the limbs. Often crying. Weak cries.

On the 14th day of the newborn infant is recovering active breathing, freedom of movement, normal CSR. Began to actively suck the mother's breast.

In the following days and the coming weeks there was a slight delay in mental and physical development of the child.

After 6 months assigned to the course (re) treatment under the proposed method with a daily injection of 50 mg of the drug in saline solution. See stable development of the child.

Later the child became as close as possible to the physical and psycho-emotional development of their peers.

Example 2. A sick child, s Michael, 6 years. Diagnosis: cerebral palsy. Born in time, grade Apgar 6 points. Further grew and developed, lagging behind peers. Started to go in 2 years, 1 month.

Was identified tetraparesis, more pronounced in the legs. Atrophy of all muscle groups with a high tone. Moves independently, but walking is difficult. Gait, spastic-pateticheskaja. Mentally Zamacona poor. Poor emotional reactions. Sleep broken, choppy, poor sleep.

Patient In-Woo Misha intramuscularly 50 mg oxitetraciclina succinate 1 time per day. Conducting a course of 16 days. During the course and after the child has animated facial expressions, he became more cheerful, active in the periodic lessons of General development. Awakened interest in games with peers.

After 6 months, designate a refresher course on this way. Upon completion of this course the child had improved motor function. Improved gait. Decreased muscle tone. Interested in the exercises at the gym. In cognitive asks peers to teach it available games.

Improved learning with the teacher. Improved memory. Increased attention. Became more contact with peers. Preparing to enroll in a regular school.

The effectiveness of the method

The treatment results for the prototype and the proposed method are presented in the table, which recorded the fact more quickly improve brain function and reduce treatment time.

Comparative results in terms of treatment slurs.

Conclusions: in the proposed method achieved:

1. Faster recovery of motor function, higher by 33 % in comparison with the prototype.

2. The mental function of the brain, above 28% in comparison with the prototype.

3. The decrease in the degree of functional disorders of 55% (improving sleep, reducing anxiety, worry, fear, the appearance of interests, contacts with peers) in comparison with the prototype.

4. Reduction of terms of treatment for 6-8 days in comparison with the prototype.

Sources of information

1. Semenov, K. A. cerebral palsy. The treatment of movement disorders in children with cerebral paralysis. M.: Medicine, 1976.

2. Cerebral palsy/ Century A. Bronnikov and others - Perm: Hello. - 2000. - 255 S.: ill.

The method of treatment of cerebral palsy, including injection drugs, characterized in that the infant is injected intramuscularly 25 mg oxitetraciclina succinate 1 time per day for 12 days with a repeat treatment after 6 months and increasing doses of the specified drug to 50 mg, and the child is older than 1 year intramuscularly 50 mg oxitetraciclina succinate 1 time per day for 1

 

Same patents:

The invention relates to the field of medicine for a stimulator of expression of MAG (myelin-associated glycoprotein) containing the compound of formula (I):

The connection is suitable for the treatment of diseases, representing hypomyelination, demyelinization or demyelination

The invention relates to new derivatives of galantamine General formula I:

where R1-R5, G1-G3and W have the meanings indicated in the claims, and the invention relates to a method for producing these compounds, medicinal product and the method of its production

The invention relates to medicine, in particular to endocrinology, and for the treatment of complications of diabetes - neuropathy

The invention relates to the field of medicine and relates to a pharmaceutical composition having anticonvulsant and psychotropic action

The invention relates to the field of medicine and relates to a pharmaceutical composition having anticonvulsant and psychotropic action

The invention relates to medicine, in particular for orthopedics and neurosurgery, vertebrology, and can be used in the intervertebral disc

The invention relates to pharmaceutical

The invention relates to pharmaceutical

The invention relates to pharmaceutical

The invention relates to pharmaceutical

The invention relates to medicine, namely to multicomponent infusion solutions with detoxification, hepatoprotective effect, and can be used in the intoxication of the organism of various severity
The invention relates to medicine, in particular to neuropathology and treatment of neurological manifestations of osteochondrosis physical factors, and can be used in hospitals, clinics, sanatoria, preventoria, home

The invention relates to the field creating means having an antimicrobial effect on local purulent-inflammatory processes of the soft tissues
The invention relates to medicine, in particular, to obstetrics

The invention relates to medicine, in particular to the gynecologist, and can be used in the treatment of diseases of the vagina

The invention relates to the field of neurological diseases and can be used in complex treatment of patients with acute and chronic pain syndromes
The invention relates to the field of medicine

The invention relates to medicine, to afferent therapy, and can be used to treat hepatorenal syndrome in patients with decompensated liver cirrhosis complicated by ascites syndrome
The invention relates to medicine, namely to dermatology
The invention relates to medicine, ophthalmology

The invention relates to the field of medicine for a stimulator of expression of MAG (myelin-associated glycoprotein) containing the compound of formula (I):

The connection is suitable for the treatment of diseases, representing hypomyelination, demyelinization or demyelination

Up!